Problem: 5-ALA has been used for many years at relatively high dose amounts in single doses for photodynamic therapy and immunofluorescence of tumors. An analysis of compiled data relating to safety and any side-effects about the use of 5-ALA at low doses has not yet been published. Purpose: This report analyzes data about the safety of the use of 5-Aminolevulinic Acid (5-ALA) in low doses as a supplement over an extended period of time. Methods: This investigation is a systematic analysis of the current literature ((Medline, and SBI) and snowballing techniques) related to the safety and efficacy of 5-ALA in animals and humans. Clinical trials in progress using 5-ALA were also analyzed. Constant comparative analyses were used to synthesize the findings. Results: The safety of low-dose 5-ALA as a supplement has been demonstrated by animal and human studies. The results suggest that none of the investigations document the presence of symptoms or abnormal laboratory results of clinical significance. The minor laboratory changes documented were judged not clinically significant.
B. L. Rodriguez, J. D. Curb, J. Davis, T. Shintani, M. H. Perez, N. Apau-Ludlum, et al., “Use of the Dietary Supplement 5-Aminiolevulinic Acid (5-ALA) and Its Relationship with Glucose Levels and Hemoglobin A1C among Individuals with Prediabetes,” Clinical and Translational Science, Vol. 5, No. 4, 2012, pp. 314-320.
A. Gorchein and R. Webber, “Delta-Aminolaevulinic Acid in Plasma, Cerebrospinal Fluid, Saliva and Erythrocytes: Studies in Normal, Uraemic and Porphyric Subjects,” Clinical Science (Lond), Vol. 72, 1987, pp. 103-112.
T. Yamamoto, “Technical Reports SBI ALA Promo Co Ltd. Study on the Safety of Oral ALA Phosphate in Healthy Adults,” Meguro Medical Clinic, Medical Corporation Yukokai, Contact Research Organization TTC Co. Ltd., Tokyo.
W. Stummer, U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella, H. J. Reulen, et al., “Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial,” Lancet Oncology, Vol. 7, No. 5, 2006, pp. 392-401. http://dx.doi.org/10.1016/S1470-2045(06)70665-9
R. Ritz, G. C. Feigl, M. U. Schuhmann, A. Ehrhardt, S. Danz, S. Noell, A. Bornemann and M. S. Tatagiba, “Use of 5-ALA Fluorescence Guided Endoscopic Biopsy of a Deep-Seated Primary Malignant Brain Tumor,” Journal of Neurosurgery, Vol. 114, No. 5, 2011, pp. 1410-1413.
K. A. Morton, P. Kushner, J. G. Straka and B. F. Burnham, “Biosynthesis of 5-Aminolevulinic Acid and Heme from 4,5-Dioxovalerate in the Rat,” Journal of Clinical Investigation, Vol. 71, No. 6, 1983, pp. 1744-1749. http://dx.doi.org/10.1172/JCI110929
H. Suzuki, “Study on the Safety of Oral ALA Phosphate (Alone and in Combination with Sodium Ferrous Citrate),” Contract Research Organization: TTC Co., Ltd., Tokyo, 2008, Healthy Adults Protocol No. 19474.
H. T. Ji, L. T. Chien, Y. H. Lin, H. F. Chien and C. T. Chen, “5-ALA Mediated Photodynamic Therapy Induces Autophagic Cell Death via AMP-Activated Protein Kinase,” Molecular Cancer, Vol. 9, 2010, p. 91.
C. Mingone, S. Gupte, J. Chow, M. Ahmad, N. Abraham and M. Wolin, “Protoporphyrin Generation from Aminolevulinic Acid Elicits Pulmonary Artery Relaxation and Soluble Guanylate Cyclase Activation,” American Journal of Physiology—Lung Cellular and Molecular Physiology, Vol. 29, 2006, pp. L337-L344.
S. Ogura, K. Maruyama, Y. Hagiya, Y. Sugiyama, K. Tsuchiya, K. Takahashi, F. Abe, K. Tabata, I. Okura, M. Nakajima, et al., “The Effect of 5-Aminolevulinic Acid on Cytochrome Coxidase Activity in Mouse Liver,” BMC Research Notes, Vol. 4, No. 1, 2011, p. 66.